Jessica Franke
Primary Care · Glen Dale, WVNPI 1760036479
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 24.5% of the total. Reporting peaked in 2023 at $843 and has fallen 78.1% since, to $185 in 2025.
Across 143 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$554
- Lilly USA, LLC$361
- AstraZeneca$310
- Amgen$266
- AbbVie$206
- Sanofi$129
- plus $439 from 10 others
What the payments were for
- Food & beverage$2,23999%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $554 |
| Lilly USA, LLC | 22 | $361 |
| AstraZeneca | 22 | $310 |
| Amgen | 17 | $266 |
| AbbVie | 12 | $206 |
| Sanofi | 1 | $129 |
| Teva Pharmaceuticals USA, Inc. | 6 | $94 |
| Pfizer | 6 | $91 |
| GSK | 4 | $67 |
| Boehringer Ingelheim | 3 | $54 |
| Amarin Pharma, Inc. | 2 | $39 |
| Shield Therapeutics Inc | 2 | $30 |
| Bayer | 1 | $18 |
| Novartis | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$129
How this compares
$2,264 in reported general payments places this provider in the 80th percentile of 43 primary care providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $81,208 |
| EliquisApixaban | 42 | $42,937 |
| FarxigaDapagliflozin Propanediol | 35 | $40,189 |
| MounjaroTirzepatide | 24 | $24,732 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $20,202 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $19,217 |
| TrulicityDulaglutide | 19 | $19,156 |
| JardianceEmpagliflozin | 13 | $18,180 |
| XareltoRivaroxaban | 16 | $13,747 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,588 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $5,512 |
| Rosuvastatin Calcium | 144 | $2,289 |
| Potassium Chloride | 42 | $1,591 |
| Esomeprazole Magnesium | 27 | $1,440 |
| Atorvastatin Calcium | 104 | $1,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $554 | $81,20863 claims |
| Lilly USA, LLCMounjaro, Trulicity | $361 | $43,88843 claims |
| PfizerEliquis | $91 | $42,93742 claims |
| AstraZenecaFarxiga | $310 | $40,18935 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $54 | $23,76824 claims |
| GSKTrelegy Ellipta | $67 | $20,20217 claims |
| Johnson & JohnsonXarelto | $15 | $13,74716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 primary care providers in West Virginia.
Other primary care in Glen Dale
- Brenda DennisGlen Dale$6K
- Amanda WakimWheeling$169K
- Brenda HashemBerkeley Springs$8K
- Molly WhiteCharleston$5K
- Richard SutherlandMartinsburg$4K
- Kayla MeadeHuntington$3K
- Crystal Clark-CrookshanksSummersville$3K
- Jerica BoboRomney$2K
- Alisa EllisonHinton$2K
- Amber BellMorgantown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.